vs
Medpace Holdings, Inc.（MEDP）与ROYAL GOLD INC（RGLD）财务数据对比。点击上方公司名可切换其他公司
Medpace Holdings, Inc.的季度营收约是ROYAL GOLD INC的1.9倍（$708.5M vs $375.3M），ROYAL GOLD INC净利率更高（24.9% vs 19.1%，领先5.9%），ROYAL GOLD INC同比增速更快（85.3% vs 32.0%），过去两年ROYAL GOLD INC的营收复合增速更高（58.8% vs 17.7%）
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
Royal Gold Inc.是全球领先的贵金属流权与特许权经营企业，收购并管理多元化的矿业项目流权、净熔炼收益特许权及相关权益，资产覆盖黄金、白银、铜等品类，业务遍及多地区，无需直接承担采矿运营风险。
MEDP vs RGLD — 直观对比
营收规模更大
MEDP
是对方的1.9倍
$375.3M
营收增速更快
RGLD
高出53.3%
32.0%
净利率更高
RGLD
高出5.9%
19.1%
两年增速更快
RGLD
近两年复合增速
17.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $708.5M | $375.3M |
| 净利润 | $135.1M | $93.6M |
| 毛利率 | — | 64.6% |
| 营业利润率 | 21.6% | 56.2% |
| 净利率 | 19.1% | 24.9% |
| 营收同比 | 32.0% | 85.3% |
| 净利润同比 | 15.5% | -12.8% |
| 每股收益（稀释后） | $4.65 | $1.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MEDPRGLD
| Q4 25 | $708.5M | $375.3M | ||
| Q3 25 | $659.9M | $252.1M | ||
| Q2 25 | $603.3M | $209.6M | ||
| Q1 25 | $558.6M | $193.4M | ||
| Q4 24 | $536.6M | $202.6M | ||
| Q3 24 | $533.3M | $193.8M | ||
| Q2 24 | $528.1M | $174.1M | ||
| Q1 24 | $511.0M | $148.9M |
净利润MEDPRGLD
| Q4 25 | $135.1M | $93.6M | ||
| Q3 25 | $111.1M | $126.8M | ||
| Q2 25 | $90.3M | $132.3M | ||
| Q1 25 | $114.6M | $113.5M | ||
| Q4 24 | $117.0M | $107.4M | ||
| Q3 24 | $96.4M | $96.2M | ||
| Q2 24 | $88.4M | $81.2M | ||
| Q1 24 | $102.6M | $47.2M |
毛利率MEDPRGLD
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 73.6% | ||
| Q2 25 | — | 72.6% | ||
| Q1 25 | — | 69.4% | ||
| Q4 24 | — | 70.3% | ||
| Q3 24 | — | 66.6% | ||
| Q2 24 | — | 64.7% | ||
| Q1 24 | — | 58.4% |
营业利润率MEDPRGLD
| Q4 25 | 21.6% | 56.2% | ||
| Q3 25 | 21.5% | 64.4% | ||
| Q2 25 | 20.9% | 67.7% | ||
| Q1 25 | 20.3% | 63.6% | ||
| Q4 24 | 23.4% | 65.9% | ||
| Q3 24 | 21.1% | 61.3% | ||
| Q2 24 | 19.9% | 58.6% | ||
| Q1 24 | 20.4% | 50.7% |
净利率MEDPRGLD
| Q4 25 | 19.1% | 24.9% | ||
| Q3 25 | 16.8% | 50.3% | ||
| Q2 25 | 15.0% | 63.1% | ||
| Q1 25 | 20.5% | 58.7% | ||
| Q4 24 | 21.8% | 53.0% | ||
| Q3 24 | 18.1% | 49.7% | ||
| Q2 24 | 16.7% | 46.6% | ||
| Q1 24 | 20.1% | 31.7% |
每股收益（稀释后）MEDPRGLD
| Q4 25 | $4.65 | $1.04 | ||
| Q3 25 | $3.86 | $1.92 | ||
| Q2 25 | $3.10 | $2.01 | ||
| Q1 25 | $3.67 | $1.72 | ||
| Q4 24 | $3.67 | $1.63 | ||
| Q3 24 | $3.01 | $1.46 | ||
| Q2 24 | $2.75 | $1.23 | ||
| Q1 24 | $3.20 | $0.72 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $497.0M | $233.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $459.1M | $7.2B |
| 总资产 | $2.0B | $9.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MEDPRGLD
| Q4 25 | $497.0M | $233.7M | ||
| Q3 25 | $285.4M | $172.8M | ||
| Q2 25 | $46.3M | $248.2M | ||
| Q1 25 | $441.4M | $240.8M | ||
| Q4 24 | $669.4M | $195.5M | ||
| Q3 24 | $656.9M | $127.9M | ||
| Q2 24 | $510.9M | $74.2M | ||
| Q1 24 | $407.0M | $137.9M |
总债务MEDPRGLD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $50.0M | ||
| Q1 24 | — | — |
股东权益MEDPRGLD
| Q4 25 | $459.1M | $7.2B | ||
| Q3 25 | $293.6M | $3.4B | ||
| Q2 25 | $172.4M | $3.3B | ||
| Q1 25 | $593.6M | $3.2B | ||
| Q4 24 | $825.5M | $3.1B | ||
| Q3 24 | $881.4M | $3.0B | ||
| Q2 24 | $763.6M | $3.0B | ||
| Q1 24 | $671.5M | $2.9B |
总资产MEDPRGLD
| Q4 25 | $2.0B | $9.5B | ||
| Q3 25 | $1.8B | $4.5B | ||
| Q2 25 | $1.6B | $3.6B | ||
| Q1 25 | $1.9B | $3.5B | ||
| Q4 24 | $2.1B | $3.4B | ||
| Q3 24 | $2.1B | $3.3B | ||
| Q2 24 | $1.9B | $3.3B | ||
| Q1 24 | $1.8B | $3.3B |
负债/权益比MEDPRGLD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.02× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $192.7M | $241.7M |
| 自由现金流经营现金流 - 资本支出 | $188.1M | — |
| 自由现金流率自由现金流/营收 | 26.6% | — |
| 资本支出强度资本支出/营收 | 0.6% | — |
| 现金转化率经营现金流/净利润 | 1.43× | 2.58× |
| 过去12个月自由现金流最近4个季度 | $681.9M | — |
8季度趋势，按日历期对齐
经营现金流MEDPRGLD
| Q4 25 | $192.7M | $241.7M | ||
| Q3 25 | $246.2M | $174.0M | ||
| Q2 25 | $148.5M | $152.8M | ||
| Q1 25 | $125.8M | $136.4M | ||
| Q4 24 | $190.7M | $141.1M | ||
| Q3 24 | $149.1M | $136.7M | ||
| Q2 24 | $116.4M | $113.5M | ||
| Q1 24 | $152.7M | $138.3M |
自由现金流MEDPRGLD
| Q4 25 | $188.1M | — | ||
| Q3 25 | $235.5M | — | ||
| Q2 25 | $142.4M | — | ||
| Q1 25 | $115.8M | — | ||
| Q4 24 | $183.0M | — | ||
| Q3 24 | $138.5M | — | ||
| Q2 24 | $103.5M | — | ||
| Q1 24 | $147.2M | — |
自由现金流率MEDPRGLD
| Q4 25 | 26.6% | — | ||
| Q3 25 | 35.7% | — | ||
| Q2 25 | 23.6% | — | ||
| Q1 25 | 20.7% | — | ||
| Q4 24 | 34.1% | — | ||
| Q3 24 | 26.0% | — | ||
| Q2 24 | 19.6% | — | ||
| Q1 24 | 28.8% | — |
资本支出强度MEDPRGLD
| Q4 25 | 0.6% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.4% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 2.4% | — | ||
| Q1 24 | 1.1% | — |
现金转化率MEDPRGLD
| Q4 25 | 1.43× | 2.58× | ||
| Q3 25 | 2.22× | 1.37× | ||
| Q2 25 | 1.65× | 1.15× | ||
| Q1 25 | 1.10× | 1.20× | ||
| Q4 24 | 1.63× | 1.31× | ||
| Q3 24 | 1.55× | 1.42× | ||
| Q2 24 | 1.32× | 1.40× | ||
| Q1 24 | 1.49× | 2.93× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
RGLD
| Gold | $216.9M | 58% |
| Pueblo Viejo | $47.3M | 13% |
| Andacollo | $32.6M | 9% |
| Silver | $32.1M | 9% |
| Other | $27.2M | 7% |
| Copper | $13.7M | 4% |
| Cortez Legacy Zone | $5.4M | 1% |
